相关实验视频

Updated: Sep 17, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

与阿尔茨海默病患者的莱卡内马布治疗相关的脑腔形变化

Nicholas U Schwartz¹, Connor D Dietz¹, Igor Prufer Araújo¹

¹Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco; and.

Neurology. Clinical practice

|June 30, 2025

概括

在患有洞穴性形的阿尔茨海默氏症患者中,Lecanemab治疗导致了形的无症状扩张. 这表明,在抗粉胺免疫疗法期间,需要对这些血管病变的患者进行仔细监测.

科学领域:

神经学神经学
神经成像是一种神经成像.
药理学药理学是指药理学的学科.

背景情况:

抗粉胺免疫疗法携带脑内出血的风险,特别是与APOE-ε4载体等因素.
患有洞穴性形的患者被排除在试验之外,因此这些治疗方法的风险概况尚不清楚.

研究的目的:

报告一个用lecanemab治疗的阿尔茨海默氏病 (AD) 病例,该病例有偶发的洞穴形.
评估lecanemab在患有AD和同时存在洞穴形的患者的安全性和作用.

主要方法:

一名73岁的女性患有轻度认知障碍和AD生物标志物,接受了静脉注射lecanemab.
基线MRI显示微出血和无症状的轨道前腔腔形形.
在整个lecanemab治疗期间,连续的MRI监测了洞穴形.

主要成果:

洞穴性形最初保持稳定,但在13次输液后,通过血液制品显示无症状的大小增加.
没有观察到新的粉样蛋白相关成像异常 (ARIA).
由于形变化,莱卡尼马布治疗被中止.

结论:

在这种AD患者中,莱卡涅马布治疗与偶发性洞穴形的无症状扩张有关.
这一案例凸显了lecanemab可能影响预先存在的血管病变的潜力,即使没有ARIA.
需要进一步的研究,以了解抗粉胺疗法的风险,在患有洞穴性形的患者.

更多相关视频

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Published on: September 4, 2017

Isolation and Cannulation of Cerebral Parenchymal Arterioles

Isolation and Cannulation of Cerebral Parenchymal Arterioles

Published on: May 23, 2016

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...